Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CCR8 monoclonal antibody S-531011

A human immunoglobulin G1 (IgG1) monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody S-531011 targets, binds to and blocks the activity of CCR8 on CCR8-positive tumor-infiltrating regulatory T cells (Tregs) in the tumor microenvironment (TME) and prevents chemokine ligand 1 (CCL1)-CCR8-mediated signaling. S-531011 eliminates CCR8-positive Tregs via the induction of Fc-mediated antibody-dependent cell-mediated cytotoxicity (ADCC), thereby depleting CCR8-positive Tregs. This may reactivate antitumor immune responses. CCR8 is specifically expressed by tumor-infiltrating Tregs in multiple types of cancer and plays a key role in immunosuppression. High expression is correlated with poor prognosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-C-C-chemokine receptor 8 monoclonal antibody S-531011
Code name:S 531011
S-531011
S531011
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search